Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-16T22:21:18.054Z Has data issue: false hasContentIssue false
  • English
  • Français

Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant

Published online by Cambridge University Press:  15 May 2009

J. A. Mumford ,
H. Wilson ,
D. Hannant  and
D. M. Jessett
J. A. Mumford
Affiliation:
Department of Infectious Diseases, Animal Health Trust, P.O. Box 5, Newmarket, UK
H. Wilson
Affiliation:
Solvay Duphar B.V., P.O. Box 900, 1380 DA, Weesp, Holland
D. Hannant
Affiliation:
Department of Infectious Diseases, Animal Health Trust, P.O. Box 5, Newmarket, UK
D. M. Jessett
Affiliation:
Department of Infectious Diseases, Animal Health Trust, P.O. Box 5, Newmarket, UK
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Equine influenza vaccines containing inactivated whole virus and Carbomer adjuvant stimulated higher levels and longer lasting antibody to haemagglutinin in ponies than vaccines of equivalent antigenic content containing aluminium phosphate adjuvants. Five months after the third dose of vaccine containing Carbomer adjuvant, ponies were protected against clinical disease induced by an aerosol of virulent influenza virus (A/equine/Newmarket/79, H3N8). In contrast ponies which received vaccine containing aluminium phosphate adjuvant were susceptible to infection and disease. There was an inverse correlation between prechallenge levels of antibody detected by single radial haemolysis (SRH) and duration of virus excretion, pyrexia and coughing. All ponies with antibody levels equivalent to SRH zones of ≥ 154 mm2 were protected against infection and all those with levels ≤ 85 mm2 were protected from disease.

Type
Research Article
Information
Epidemiology & Infection , Volume 112 , Issue 2 , April 1994 , pp. 421 - 437
Copyright
Copyright © Cambridge University Press 1994

References

REFERENCES

Hinshaw, VSNaeve, CW, Webster, RG, Douglas, ASkehel, JJBryans, J. Analysis of antigenic variation in equine 2 influenza A viruses. Bull WHO 1983: 61: 153–8.Google ScholarPubMed
Burrows, R, Spooner, PR, Goodridge, D. A three-year evaluation of four commercial equine influenza vaccines in ponies maintained in isolation. International Symposium on Influenza Immunisation (II) 1977; 39: 341–6.Google ScholarPubMed
Mumford, JA, Wood, JM, Folkers, C, Schild, G. Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus. Epidemiol Infect 1988: 100: 501–10.CrossRefGoogle ScholarPubMed
Wood, JM, Schild, GC, Folkers, C, Mumford, J, Newman, RW. The standardisation of inactivated equine influenza vaccines by single–radial immunodiffusion. J Biol Stand 1983; 11: 133–6.CrossRefGoogle ScholarPubMed
Mumford, JA, Wood, JMScott, AM, Folkers, C, Schild, GC. Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). J Hyg 1983; 90: 385–95.CrossRefGoogle ScholarPubMed
Burrows, R, Goodridge, D, Denyer, M, Hutchings, GFrank, CJ. Equine influenza infections in Great Britain 1979. Vet Rec 1982; 110: 494–7.CrossRefGoogle ScholarPubMed
7. Carbomer 934P. USP XXII, NF XVII. United States Pharmacopeial Convention Inc., Rockville. Maryland, 1990: 1911.Google Scholar
Mumford, JAHannant, D, Jessett, DM. Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols. Equine Vet J 1990: 22: 93–8.CrossRefGoogle ScholarPubMed
Wood, JMMumford, JFolkers, C, Scott, AM, Schild, GC. Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. J Hyg 1983: 90: 371–84.CrossRefGoogle ScholarPubMed
Haaheim, LR, Schild, GC. Antibodies to strain–specific and cross–reactive determinants of the haemagglutinin of influenza H3N8 viruses. Acta Path Microbiol Scand (Section B) 1980; 88: 335–40.Google Scholar
Virelizier, JL. Host defences against influenza; the role of anti–haemagglutinin antibody. J Immunol 1975; 115: 434–9.CrossRefGoogle Scholar
Hannant, D, Jessett, DMO'Neill, T, Sundquist, B, Mumford, JA. Nasopharyngeal, tracheobronchial, and systemic immune responses to vaccination and aerosol infection with equine–2 influenza A virus (H3N8). In: Powell, DG ed. Proceedings of the 5th International Conference on Equine Infectious Diseases. Lexington: Kentucky University Press, 1988: 66–73.Google Scholar
Hannant, D, Mumford, JA. Cell mediated immune responses in ponies following infection with equine influenza virus (H3N8): the influence of induction culture conditions on the properties of cytotoxic effector cells. Vet Immunol Immunopath 1989; 21: 327–37.CrossRefGoogle ScholarPubMed